This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Bristol-Myers Squibb And Pfizer Announce New Data On Stroke Prevention In Atrial Fibrillation To Be Presented At American Heart Association 2012 Scientific Sessions

Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced that a large number of data presentations sponsored by the companies on ELIQUIS ® (apixaban) and the treatment of atrial fibrillation will be presented at the American Heart Association 2012 Scientific Sessions, November 3-7, 2012, in Los Angeles, California. Among the presentations are two prespecified subanalyses from the ARISTOTLE trial: a more detailed analysis of ISTH major bleeding with ELIQUIS versus warfarin and an evaluation of the safety and efficacy of ELIQUIS versus warfarin in patients with prior warfarin experience (warfarin-experienced compared with warfarin-naïve). Also being presented is a subanalysis from ARISTOTLE of the safety and efficacy of ELIQUIS versus warfarin in patients with prior coronary artery disease. The ARISTOTLE trial evaluated the efficacy and safety of ELIQUIS, an investigational compound for the prevention of stroke or systemic embolism, in patients with nonvalvular atrial fibrillation compared with warfarin.

Company-sponsored real-world data analyses providing relevant insights on management of atrial fibrillation and experience with warfarin, such as the correlation between bleeding and discontinuation, warfarin outcomes in the real-world compared to trial data, and early ischemic outcomes after warfarin initiation will also be presented.

Details on the ARISTOTLE data analyses and real-world data analyses at the congress are as follows:

 
ARISTOTLE SUBANALYSES
Session Details   Presentation Title   Lead Author
Monday

November 5, 2012

10:45–11:00 PST

Abstract Oral Session

Room 403a

  Apixaban in Patients with Atrial Fibrillation and Prior Coronary Artery Disease: Insights from the ARISTOTLE Trial   Maria Cecilia Bahit, MD, ECLA, Rosario, Argentina
Monday

November 5, 2012

11:15-11:30 PST

Abstract Oral Session

Hall A-10

  Apixaban versus Warfarin in Patients with Atrial Fibrillation in Relation to Prior Warfarin Use: Insights from the ARISTOTLE Trial   David A. Garcia, MD, University of New Mexico, Albuquerque, NM
Tuesday

November 6, 2012

3:00–4:30 PST

Abstract Poster Session

Kentia Hall, Core 2, Poster Board: 2068

  Reduction in Bleeding with Apixaban versus Warfarin is Consistent Across Subgroups and Locations: Insights from the ARISTOTLE Trial   Elaine M. Hylek, MD, Boston University, Boston, MA
OUTCOMES RESEARCH/REAL-WORLD DATA
Session Details   Presentation Title   Lead Author
Sunday

November 4, 2012

9:30–11:00 PST

Abstract Poster Session

Kentia Hall, Core 2, Poster Board: 2117

  Post-Discharge Stroke in Patients With Atrial Fibrillation: A Follow-Up Study in Major Cities of China   Bao Liu, Ph.D., School of Public Health, Fudan University, Shanghai, China
Sunday

November 4, 2012

3:00–4:30 PST

Abstract Poster Session

Kentia Hall, Core 2, Poster Board: 2094

  The Association Between Bleeding and Warfarin Discontinuation in Patients with Atrial Fibrillation   Xianying Pan, Bristol-Myers Squibb, Wallingford, CT
Monday

November 5, 2012

9:30–11:00 PST

Best of AHA Specialty Conferences

  Exposure to Warfarin and the Risks of Stroke and Bleeding Events among Patients with Non-Valvular Atrial Fibrillation: Real-World vs. Clinical Trial   Alpesh Amin, MD, University of California, Irvine, Irvine, CA
Tuesday

November 6, 2012

9:30–11:00 PST

Abstract Poster Session

Kentia Hall, Core 2, Poster Board: 2176

  Impact of Bleeding on Length of Stay and Total Cost in Atrial Fibrillation Patients   Alpesh Amin, MD, University of California, Irvine, Irvine, CA
Tuesday

November 6, 2012

9:30–11:00 PST

Abstract Poster Session

Kentia Hall, Core 2, Poster Board: 2177

  Evaluation of Patient-Reported Disease Burden of Atrial Fibrillation   Liu Xianchen, Pfizer Inc., New York, NY
Tuesday

November 6, 2012

9:30–11:00 PST

Abstract Poster Session

Kentia Hall, Core 2, Poster Board: 2175

  Utilization Patterns of Anticoagulants in Non-Valvular Atrial Fibrillation after the entry of Novel Oral Anticoagulants in the United States   Melissa Hamilton, MPH, Bristol-Myers Squibb, Princeton, NJ
Wednesday

November 7, 2012

9:15–9:30 PST

Abstract Oral Session

Room 511

  Early Effects on Ischemic Strokes After Initiation of Warfarin in Patients With Atrial Fibrillation   Laurent Azoulay, Ph.D., M.Sc., Jewish General Hospital, Montreal, Canada
Wednesday

November 7, 2012

9:30–11:30 PST

Abstract Poster Session

Kentia Hall, Core 2, Poster Board: 2051

  Tolerability of Apixaban — Insights From A Meta-Analysis of Discontinuation Rates in Randomized Trials   Ria Kundu, MD, University of Toledo, Toledo, OH

About Atrial Fibrillation

Atrial fibrillation is the most common cardiac arrhythmia (irregular heart beat). It is estimated that more than 5.8 million Americans and 6 million individuals in Europe have atrial fibrillation. The lifetime risk of developing atrial fibrillation is estimated to be approximately 25 percent for individuals 40 years of age or older. One of the most serious medical concerns for individuals with atrial fibrillation is the increased risk of stroke, which is five times higher in people with atrial fibrillation than those without atrial fibrillation. In fact, 15 percent of all strokes are attributable to atrial fibrillation in the U.S. Additionally, strokes due to atrial fibrillation are more burdensome than strokes due to other causes. Atrial fibrillation-related strokes are more severe than other strokes with an associated 30-day mortality of 24 percent and a 50 percent likelihood of death within one year in patients who are not treated with an antithrombotic.

Stock quotes in this article: BMY, PFE 

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,428.02 +3.17 0.02%
S&P 500 1,868.74 +6.43 0.35%
NASDAQ 4,107.2880 +21.0630 0.52%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs